Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
Russ Conroy
Articles by Russ Conroy
Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.